Table 1: Demographic and Illness Features: Male Participants.
Data are presented as mean ± standard deviation and range (min-max) unless otherwise noted. ART: Anti-retroviral therapy, ARV: Anti-retrovirals; BDI-II: Beck’s Depression Inventory – 2nd Edition; NS: Not significant; WRAT: Wide Range Achievement Test
| HIV−/METH− (n=42) | HIV−/METH+ (n=29) | HIV+/METH− (n=47) | HIV+/METH+ (n=42) | Statistics | |
|---|---|---|---|---|---|
| Age (yrs) | 35.7 ± 13.0 (18-64) | 37.0 ± (21-60) | 41.0 ± 10.8 (23-70) | 39.4 ± 6.6 (24-54) | HIV+ groups > HIV− groups |
| Ethnicity (n) | 6 Afr. Am. 10 Hisp. 0 Asian 25 Cauc. 1 Other | 8 Afr. Am. 5 Hisp. 0 Asian 16 Cauc. 0 Other | 9 Afr. Am. 13 Hisp. 2 Asian 22 Cauc. 1 Other | 4 Afr. Am. 10 Hisp. 0 Asian 27 Cauc. 1 Other | NS |
| Education (yrs) | 14.4 ± 2.2A (10-20) | 12.7 ± 2.2B (9-18) | 14.2 ± 2.1A (9-18) | 14.1 ± 2.6A,B (8-20) | Groups with the same letters are not significantly different |
| WRAT-4 Score | 105 ± 11A (82-131) | 97 ± 9B (83-116) | 103 ± 11A,B (83-130) | 106 ± 13A (87-131) | Groups with the same letters are not significantly different |
| Global Deficit Score | 0.20 ± 0.21 (0-0.95) | 0.37 ± 0.39 (0-1.44) | 0.34 ± 0.30 (0-1.11) | 0.48 ± 0.45 (0-1.67) | HIV+ groups > HIV− groups; METH+ groups > METH− groups |
| BDI-II Total Score | 2.3 ± 3.3 (0-13) | 13.7 ± 10.9 (0-35) | 11.6 ± 13.3 (0-58) | 13.7 ± 12.0 (0-47) | HIV+ groups> HIV− groups; METH+ groups > METH− groups |
| Lifetime Substance Use Disorder (n) | 20 | 29 | 22 | 42 | Chi-squared: p<0.0005 |
| Age First METH use (yrs) | - | 22.4 ± 11.0 (8-56) | - | 25.1 ± 7.6 (13-48) | NS |
| Days since last METH use (days) | - | 197 ± 407 (4-2191) | - | 117 ± 126 (1-426) | NS |
| Total days METH use (days) | - | 2262 ± 1961 (86-8797) | - | 1744 ± 1819 (59-9771) | NS |
| Total quantity METH use (grams) | - | 4131 ± 8182 (35-40185) | - | 1961 ± 4413 (12-26526) | NS |
| Current CD4+ Cell Count | - | - | 645 ± 301 (81 – 1712) | 563 ± 231 (82 – 1053) | NS |
| Nadir CD4+ Cell Count | - | - | 319 ± 220 (3-800) | 282 ± 182 (8-840) | NS |
| Estimated Duration HIV Infection (yrs) | - | - | 10.5 ± 9.2 (0.1-28.9) | 8.4 ± 6.4 (0.1-23.8) | NS |
| Plasma Viral Load - log10 (copies per mL) | 2.11 ± 1.21 (0.00-5.45) | 2.39 ± 1.41 (0.00-5.95) | NS | ||
| Current ART Use (n) | - | - | 35 Yes 12 No | 31 Yes 11 No | NS |
| Months Total ART Exposure | - | - | 70.4 ± 78.2 (0-275) | 59.2 ± 58.0 (0-181) | NS |
| Current Number of ARVs Using (n) | - | - | 2.7 ± 1.7 (0-6) | 2.7 ± 1.7 (0-5) | NS |
| Participants with AIDs (n) | - | - | 18 | 17 | NS |